The NCE period for tirzepatide runs through May 13, 2027, which means generic companies may not file an ANDA seeking approval for a generic version of Mounjaro or Zepbound until May 13, 2026, with patent infringement lawsuits expected to occur in the following months
Before increasing tirzepatide dosage, several safety assessments are essential
Quality-control concerns are especially important for unapproved or compounded peptides
We stand behind our products
Aerobic activity 3 to 5 times per week
We have also discussed some novel approaches that may play a role in Zn uptake and translocation under Zn deficiency, including the inoculation of arbuscular mycorrhizal fungi and rhizobacteria, the application of organic ligands in combination with nano-fertilizers, and the use of natural and synthetic chelators